Who Makes Wegovy, and What That Tells You About the Medicine

The misconception worth clearing up first: Wegovy and Ozempic are not the same product

A lot of people arrive at this question already slightly confused, and it is an entirely understandable confusion. Both Wegovy and Ozempic contain semaglutide, and both are made by Novo Nordisk. So the obvious question is: if they share a manufacturer and an active ingredient, are they basically the same thing sold under two names?

Not quite. The two medicines carry different UK licences for different clinical purposes. The full comparison between Ozempic and Wegovy covers this in detail, but the short version is this: Ozempic is licensed in the UK for type 2 diabetes management, while Wegovy is licensed specifically for weight management in adults with obesity or excess weight alongside a health condition. The MHRA treats them as distinct products. Using Ozempic for weight loss (rather than the Wegovy formulation) would be off-label, and no regulated UK pharmacy prescribes it on that basis.

The reason people conflate them is partly that early media coverage used the names interchangeably, and partly that semaglutide itself became famous as a weight-loss medicine before Wegovy had wide availability. Novo Nordisk has been consistent in separating the two products; the regulatory picture in the UK is equally clear. If you are looking for a fuller explainer on semaglutide itself, that covers the mechanism and licensing in one place.

Novo Nordisk's track record with semaglutide, and why it matters for clinical confidence

Novo Nordisk did not launch Wegovy overnight. The company spent years building an evidence base for semaglutide in weight management before seeking regulatory approval. The pivotal STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and found an average body-weight reduction of around 15% at the 2.4mg maintenance dose alongside lifestyle changes, a figure that shaped NICE's subsequent appraisal of the medicine.

That NICE appraisal (TA875) recommended Wegovy within specific NHS criteria, and NICE's assessment process scrutinises a manufacturer's data closely before any recommendation is issued. Novo Nordisk's submission passed that scrutiny. The company has since received MHRA approval for a higher 7.2mg maintenance dose (initially delivered as three standard pens weekly, then as a dedicated single-dose 7.2mg pen approved on 14 April 2026) which trials suggest can produce average weight loss approaching 20.7% over 72 weeks. The science behind how Wegovy works explains the mechanism in plain terms if you want to understand why the higher dose produces greater results.

Novo Nordisk also supplies Wegovy to the UK through the authorised supply chain, the chain of licensed wholesalers and pharmacies that the MHRA oversees. That matters because counterfeit versions of weight-loss medicines have been seized in the UK in significant quantities. Buying from a GPhC-registered pharmacy drawing on that authorised chain is the only way to be confident the medicine you receive is genuine.

What the manufacturer's licensing decisions mean for cost and access in the UK

One thing Novo Nordisk's decisions directly affect is price. In August 2025, Eli Lilly (the company behind Mounjaro, a separate GLP-1 medicine) significantly raised its UK list prices; Novo Nordisk's Wegovy has its own pricing, and private market rates vary by dose and provider. A factual breakdown of Wegovy costs in the UK is worth reading if cost is a key factor in your thinking, it covers what a legitimate price includes, and why headline figures can be misleading.

Availability on the NHS is governed not by Novo Nordisk directly but by NICE's recommendations and NHS England's commissioning decisions. Under TA875, Wegovy is currently available through specialist weight management services to patients meeting specific BMI and comorbidity criteria. Private prescriptions through a GPhC-registered pharmacy offer an alternative for people who do not meet NHS thresholds or prefer not to join a waiting list. The Wegovy treatment overview sets out both routes plainly.

Knowing who makes a medicine, and understanding the regulatory and clinical infrastructure around it, is genuinely useful context. It is not just trivia. A medicine's manufacturer shapes everything from the evidence base you can trust to the supply chain keeping counterfeits out.

Some practical details that come from Novo Nordisk's formulation choices

Novo Nordisk makes Wegovy as a once-weekly subcutaneous injection, supplied in a pre-filled pen. The standard treatment pathway begins at 0.25mg and titrates upward through 0.5mg, 1.0mg, 1.7mg, and 2.4mg over approximately 16 weeks, with the 2.4mg dose as the established maintenance level before the newer 7.2mg option. A prescriber decides the pace of that titration based on how a patient is tolerating each stage.

The company also produces Wegovy tablets, approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 medicine licensed for weight management. The tablet formulation pairs semaglutide with an absorption enhancer and is taken once daily on an empty stomach, with the maintenance dose sitting at 25mg. It requires no refrigeration, which some people find more practical. The weight-loss treatments page covers both the injection and the tablet option, so you can talk through which might suit you with our prescribers.

Side effects reported in trials are largely gastrointestinal: nausea, diarrhoea, constipation, indigestion and burping are the most common, typically most noticeable after starting or after a dose increase. Some people also notice unexpected physical changes, and if feeling unusually cold while taking Wegovy is something you have experienced, that is worth reading about to understand why it happens. If any symptoms feel severe or persistent (particularly stomach pain that spreads to the back) get medical advice promptly rather than waiting for the next scheduled check-in. That is a consistent message from Novo Nordisk's own prescribing guidance and from the MHRA alike.